An injectable cholesterol medication, known as PCSK9 inhibitors, are emerging as an effective treatment for those who cannot tolerate statins like Lipitor, or who cannot achieve goal levels of cholesterol with standard medication.
A spate of new studies published at the American College of Cardiology meetings show that these forms of medication are safe, effective at reducing cholesterol 50+%, and are well-tolerated. In addition, some of the study information shows heart attack and stroke reductions, the endpoint most important in treatment of cholesterol.
These injections will be once a week or once a month, and will work via blockage of a protein involved in LDL (bad cholesterol) clearance. The anti-PCSK9 agents include Amgen’s evolocumab, alirocumab from Sanofi and Regeneron and Pfizer’s bococizumab.
Read more >>>>>>>HERE<<<<<<.